Creating a model to predict nerve damage from cancer treatment
Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy
This study is looking to create a helpful tool that can predict which cancer patients might experience nerve damage from taxane chemotherapy, so doctors can better tailor treatments to keep you feeling your best while fighting cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11023126 on NIH RePORTER |
What this research studies
This research aims to develop a risk prediction model for taxane-induced peripheral neuropathy (TIPN), a side effect of certain cancer treatments that can severely impact daily living. By analyzing a large group of patients treated with taxane chemotherapy, the study will identify biomarkers that can predict which patients are at higher risk for developing TIPN. The approach involves collecting biospecimens and detailed data on patients' experiences with TIPN to create a clinically useful prediction tool. This model could help tailor chemotherapy treatments to minimize the risk of nerve damage while maximizing cancer treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing treatment with taxane chemotherapy who are at risk of developing peripheral neuropathy.
Not a fit: Patients who are not receiving taxane chemotherapy or those who do not experience peripheral neuropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of chemotherapy side effects, improving patients' quality of life and treatment outcomes.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for chemotherapy side effects, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Hertz, Daniel Louis — University of Michigan at Ann Arbor
- Study coordinator: Hertz, Daniel Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.